Perspective Therapeutics, Inc. (NYSE:CATX) Shares Sold by Nuveen Asset Management LLC

Nuveen Asset Management LLC cut its position in Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) by 13.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 722,048 shares of the company's stock after selling 108,165 shares during the period. Nuveen Asset Management LLC owned 1.07% of Perspective Therapeutics worth $2,303,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Perspective Therapeutics by 73.8% during the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 123,243 shares of the company's stock worth $393,000 after acquiring an additional 52,320 shares in the last quarter. Octagon Capital Advisors LP increased its stake in Perspective Therapeutics by 62.1% in the fourth quarter. Octagon Capital Advisors LP now owns 2,304,752 shares of the company's stock valued at $7,352,000 after purchasing an additional 882,528 shares during the last quarter. Millennium Management LLC acquired a new stake in Perspective Therapeutics during the fourth quarter worth approximately $4,132,000. Deutsche Bank AG raised its holdings in Perspective Therapeutics by 76.0% during the fourth quarter. Deutsche Bank AG now owns 46,579 shares of the company's stock worth $149,000 after purchasing an additional 20,120 shares in the last quarter. Finally, Deerfield Management Company L.P. Series C lifted its position in shares of Perspective Therapeutics by 4.3% during the 4th quarter. Deerfield Management Company L.P. Series C now owns 2,938,754 shares of the company's stock worth $9,375,000 after buying an additional 120,991 shares during the last quarter. 54.66% of the stock is currently owned by institutional investors and hedge funds.

Perspective Therapeutics Stock Performance

Shares of NYSE CATX traded up $0.20 during midday trading on Friday, reaching $3.32. 1,404,539 shares of the company were exchanged, compared to its average volume of 1,076,624. Perspective Therapeutics, Inc. has a 1 year low of $1.60 and a 1 year high of $16.55. The stock has a fifty day simple moving average of $2.31 and a 200 day simple moving average of $2.92.

Analyst Ratings Changes

CATX has been the topic of a number of recent analyst reports. Royal Bank of Canada raised shares of Perspective Therapeutics from an "outperform" rating to a "moderate buy" rating and increased their target price for the company from $15.00 to $16.00 in a research report on Tuesday. Wedbush reaffirmed an "outperform" rating and set a $11.00 price objective on shares of Perspective Therapeutics in a report on Tuesday, May 13th. Brookline Capital Management upgraded Perspective Therapeutics to a "strong-buy" rating in a research report on Monday, March 10th. Scotiabank started coverage on Perspective Therapeutics in a report on Friday, March 7th. They issued a "sector outperform" rating and a $15.00 target price for the company. Finally, Lifesci Capital upgraded Perspective Therapeutics to a "strong-buy" rating in a research note on Thursday, March 6th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $12.63.

Insiders Place Their Bets

In other news, Director Robert F. Williamson III acquired 38,145 shares of the business's stock in a transaction on Monday, March 31st. The stock was bought at an average price of $2.14 per share, for a total transaction of $81,630.30. Following the transaction, the director now owns 108,982 shares in the company, valued at $233,221.48. This represents a 53.85% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Juan Graham bought 33,333 shares of Perspective Therapeutics stock in a transaction dated Friday, March 28th. The stock was purchased at an average price of $2.25 per share, with a total value of $74,999.25. Following the purchase, the chief financial officer now directly owns 35,354 shares in the company, valued at approximately $79,546.50. This trade represents a 1,649.33% increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 115,696 shares of company stock valued at $256,344. 3.72% of the stock is owned by company insiders.

Perspective Therapeutics Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.